Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015-2017: a cross-sectional study.

Thomas J MooreJames HeywardGerard AndersonG Caleb Alexander

Published in: BMJ open (2020)

The estimated costs are modest for measuring the benefits of new therapeutic agents but rise exponentially as more patients and clinic visits are required to establish a drug effect.

Keyphrases

end stage renal disease
chronic kidney disease
newly diagnosed
peritoneal dialysis
physical activity
prognostic factors
emergency department
risk factors
drug induced